Unimed Innovation

Unimed Innovation is a medical technology company based in Beijing, China, specializing in the development of innovative solutions for structural heart disease. The company focuses on transcatheter valve replacement and repair technologies, including systems for the mitral, tricuspid, and aortic valves. Its lead programs, such as the Uni-Mitra and Uni-Tric systems, aim to provide minimally invasive alternatives to open-heart surgery for patients with severe valvular regurgitation. Unimed Innovation has attracted significant venture capital investment from firms like Sequoia China and Matrix Partners to advance its clinical trials and expand its product portfolio. The company is a prominent player in the interventional cardiology sector, addressing critical unmet needs in the Chinese healthcare market.